Insight

Carlyle’s Abingworth raises $356m for new clinical co-development co-investment fund

The fund will invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the U.S., UK, Europe, and Asia-Pacific.

-
  • Asante Capital Group acted as global placement advisor for CCD-CIF while Simpson Thacher & Bartlett LLP acted as legal counsel
  • Since 1973, Abingworth has invested in over 185 life science companies, leading to 49 M&As and 75 IPOs
  • Carlyle had $385 billion of assets under management as of June 30, 2023

Abingworth, a life sciences investment firm whose parent company is the Carlyle Group, has closed its new clinical co-development co-investment fund at $356 million, beating its $300 million target.

Abingworth Clinical Co-Development Co-Investment Fund will invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the U.S., UK, Europe, and Asia-Pacific.

“We are delighted to announce this new Clinical Co-Development Co-Investment Fund that, combined with Abingworth Bioventures 8 and ACCD 2, brings new funds closed by Abingworth to over $1.4 billion since 2020,” said Kurt von Emster, managing partner & head of Abingworth Life Sciences in a statement.

Asante Capital Group acted as global placement advisor for CCD-CIF while Simpson Thacher & Bartlett LLP acted as legal counsel.

Since 1973, Abingworth has invested in over 185 life science companies, leading to 49 M&As and 75 IPOs.

Carlyle had $385 billion of assets under management as of June 30, 2023.